CIK 0001390478 · Non-accelerated filer<br>Smaller reporting company
SELLAS Life Sciences Group, Inc.
Sign in to watch- Ticker
- SLS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6462005278
- Business address
- 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
- Former names
- GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-10 | Stergiou Angelos M. President and CEO | Grant or award · Stock Option (Right to Buy) | +385,750 | 385,750 | ||
| 2025-01-10 | SCHEINBERG DAVID A Director | Grant or award | +12,500 | 23,082 | ||
| 2025-01-10 | SCHEINBERG DAVID A Director | Grant or award · Stock Option (Right to Buy) | +18,500 | 18,500 | ||
| 2025-01-10 | Wasman Jane Director | Grant or award | +12,500 | 22,900 | ||
| 2025-01-10 | Wasman Jane Director | Grant or award · Stock Option (Right to Buy) | +18,500 | 18,500 | ||
| 2025-01-10 | VAN NOSTRAND ROBERT L Director | Grant or award | +12,500 | 22,900 | ||
| 2025-01-10 | VAN NOSTRAND ROBERT L Director | Grant or award · Stock Option (Right to Buy) | +18,500 | 18,500 | ||
| 2025-01-10 | Kalin Katherine Bach Director | Grant or award | +12,500 | 21,000 | ||
| 2025-01-10 | Kalin Katherine Bach Director | Grant or award · Stock Option (Right to Buy) | +18,500 | 18,500 | ||
| 2025-01-10 | Varian John Director | Grant or award | +12,500 | 22,900 | ||
| 2025-01-10 | Varian John Director | Grant or award · Stock Option (Right to Buy) | +18,500 | 18,500 | ||
| 2025-01-10 | CICIC DRAGAN SVP, Chief Development Officer | Grant or award | +113,000 | 228,328 | ||
| 2025-01-10 | CICIC DRAGAN SVP, Chief Development Officer | Grant or award | +81,300 | 309,628 | ||
| 2025-01-10 | CICIC DRAGAN SVP, Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +169,500 | 169,500 | ||
| 2024-12-04 | CICIC DRAGAN SVP, Chief Development Officer | Other disposition | −8,256 | $1.13 | $9K | 115,328 |
| 2024-12-04 | Stergiou Angelos M. President and CEO | Other disposition | −28,289 | $1.13 | $32K | 358,132 |
| 2024-12-04 | Burns John Thomas CFO | Other disposition | −7,165 | $1.13 | $8K | 104,762 |
| 2024-01-22 | Stergiou Angelos M. President and CEO | Grant or award | +159,000 | 376,421 | ||
| 2024-01-22 | Stergiou Angelos M. President and CEO | Grant or award · Stock Option (Right to Buy) | +238,500 | 238,500 | ||
| 2024-01-22 | SCHEINBERG DAVID A Director | Grant or award | +6,000 | 10,582 |
Page 2 of 8 · 141 trades